PALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone HR1/HER2-early breast cancer

被引：0
|
作者：
Mayer, E. L. [1 ]
Demichele, A. M. [2 ]
Pfeiler, G. [3 ]
Barry, W. [4 ]
Metzger, O. [5 ]
Rastogi, P. [6 ]
Symmans, F. [7 ]
Burstein, H. J. [4 ]
Miller, K. [8 ]
Loibl, S. [9 ]
Schmatloch, S. [10 ]
Goulioti, T. [11 ]
Zardavas, D. [11 ]
Fesl, C. [12 ]
Koehler, M. [13 ]
Bartlett, C. Huang [13 ]
Huang, X. [14 ]
Piccart, M. [15 ]
Winer, E. [4 ]
Gnant, M. [16 ,17 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Breast Oncol Ctr, Boston, MA USA
[2] Univ Penn, Perelman Ctr Adv Med, Philadelphia, PA 19104 USA
[3] Med Univ Vienna, Gyneol & Obstet, Vienna, Austria
[4] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[5] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[6] Univ Pittsburgh Sch Hlth Sci, Div Hematol Oncol, Pittsburgh, PA USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[8] Indiana Univ Sch Med, Hematol Oncol, Indianapolis, IN 46202 USA
[9] German Breast Grp GBG Forsch GmbH, Med & Res, Neu Isenburg, Germany
[10] Elisabeth Hosp, Senol, Kassel, Germany
[11] Breast Int Grp, Brussels, Belgium
[12] Austrian Breast & Colorectal Canc Study Grp ABCSG, Stat, Vienna, Austria
[13] Pfizer, Oncol, New York, NY USA
[14] Pfizer, Oncol, San Diego, CA USA
[15] Inst Jules Bordet, Chemotherapy Dept, Brussels, Belgium
[16] Med Univ Vienna, Dept Surg, Vienna, Austria
[17] Med Univ Vienna, Comprehens Canc Ctr, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
215TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer:: A European study
    Wengstrom, Yvonne
    Aapro, Matti
    di Priolo, Susanna Leto
    Cannon, Helena
    Georgiou, Vasoulla
    BREAST, 2007, 16 (05): : 462 - 468
  • [42] CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2-early breast cancer
    Hamilton, Erika P.
    Loibl, Sibylle
    Bachelot, Thomas
    Gnant, Michael
    Niikura, Naoki
    Park, Yeon Hee
    Tolaney, Sara M.
    Pistilli, Barbara
    Rastogi, Priya
    Saini, Kamal S.
    Gioni, Ioanna
    Johnston, Simon
    Nunes, Raquel
    Quintana, Angela
    Stuart, Mary
    Syta, Emilia
    Walding, Andrew
    Klinowska, Teresa
    Mayer, Ingrid A.
    FUTURE ONCOLOGY, 2025, 21 (07) : 795 - 806
  • [43] Quality of life from the Penelope-B study on high-risk HR+/HER2-early breast cancer patients treated with endocrine therapy with or without palbociclib
    Garcia-Saenz, J. A.
    Marme, F.
    Rugo, S.
    Untch, M.
    Bonnefoi, H.
    Kim, S-B.
    Bear, H. D.
    McCarthy, N.
    Gelmon, K.
    Martin, M.
    Kelly, C. M.
    Reimer, T.
    Toi, M.
    Law, E. H.
    Gnant, M.
    Makris, A.
    Seiler, S.
    Burchardi, N.
    Nekljudova, V.
    Loibl, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S410 - S411
  • [44] Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
    Porte, Baptiste
    Carton, Matthieu
    Loirat, Delphine
    Bidard, Francois-Clement
    Haroun, Linda
    Bellesoeur, Audrey
    Kirova, Youlia
    Cottu, Paul
    CANCER RESEARCH, 2021, 81 (04)
  • [45] Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2-early breast cancer
    O'Shaughnessy, Joyce
    Tolaney, Sara M.
    Yardley, Denise A.
    Hart, Lowell
    Razavi, Pedram
    Fasching, Peter A.
    Janni, Wolfgang
    Schwartzberg, Lee
    Kim, Julia
    Akdere, Murat
    McDermott, Courtney
    Khakwani, Aamir
    Pathak, Purnima
    Graff, Stephanie L.
    BREAST, 2025, 81
  • [46] Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
    Porte, B.
    Carton, M.
    Lerebours, F.
    Brain, E.
    Loirat, D.
    Haroun, L.
    Bellesoeur, A.
    Hamba, S. Bach
    Kirova, Y.
    Cottu, P.
    BREAST, 2020, 54 : 303 - 310
  • [47] Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2-metastatic breast cancer.
    Mayer, Erica L.
    Wander, Seth Andrew
    Regan, Meredith M.
    DeMichele, Angela
    Forero-Torres, Andres
    Rimawi, Mothaffar F.
    Ma, Cynthia X.
    Cristofanilli, Massimo
    Anders, Carey K.
    Bartlett, Cynthia Huang
    Winer, Eric P.
    Burstein, Harold J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2-early breast cancer (EBC).
    Harbeck, Nadia
    Gluz, Oleg
    Christgen, Matthias
    Graeser, Monika
    Hilpert, Felix
    Krauss, Katja
    Thill, Marc
    Warm, Mathias
    Mueller, Volkmar
    Braum, Michael Wilhelm
    Just, Marianne
    Kreipe, Hans Heinrich
    Nitz, Ulrike
    Kates, Ronald E.
    Schinkoethe, Timo
    Wuerstlein, Rachel
    Kuemmel, Sherko
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] CAPItello-292: A phase Ib/III study of capivasertib, palbociclib and fulvestrant, versus placebo, palbociclib and fulvestrant, for endocrine therapy-resistant HR+/HER2-advanced breast cancer
    Rugo, Hope S.
    Schiavon, Gaia
    Grinsted, Lynda M.
    De Bruin, Elza C.
    Catanese, Maria Teresa
    Hamilton, Erika
    CANCER RESEARCH, 2022, 82 (04)
  • [50] A phase III randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2-early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1)
    Hamilton, E.
    Loibl, S.
    Niikura, N.
    Rastogi, P.
    Saini, K. S.
    Gioni, I.
    Klinowska, T.
    Mayer, I.
    Stuart, M.
    Syta, E.
    Walding, A.
    Bachelot, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S323 - S324
12345